Laureate Pharma, Inc. has announced that it has entered into a cGMP contract manufacturing agreement with ARIUS Research, Inc., a biotechnology company focused on discovering and developing the next wave of antibody therapeutics to treat cancer and other diseases, for its Trop-2 Signal Transduction Antibody Program.
Laureate will produce ARIUS' IgG1 humanized antibody under the agreement. ARIUS' Trop-2 antibody program targets a novel marker that has been linked in the scientific literature to aggressive cancers including pancreatic, colon, breast and prostate cancer.
"Our specialized experience in the manufacture of monoclonal antibodies makes us an ideal partner to support ARIUS and the manufacturing of their Trop-2 Signal Transduction Antibody," said Robert J. Broeze, Ph.D., President & CEO of Laureate. "As with all of our Life Science client companies, we will work closely with the ARIUS team to help them achieve their manufacturing objectives."
ARIUS' Trop-2 Signal Transduction Antibody Program has produced the only unconjugated antibody currently in development targeting this novel marker. Trop-2 is a protein expressed on the cell-surface and found in many cancer indications including pancreatic, colon, breast and prostate cancer.
The target is thought to be a key part of the expansive MAPK pathway. Of more than 900 abstracts considered for oral presentation at the October 2007 AACR- NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, the abstract on Trop-2 was one of 12 selected.
The Trop-2 Signal Transduction Program was generated using ARIUS' proprietary FunctionFIRST™ technology, which selects antibodies based on their ability to kill cancer cells.